we dream world best- HAIM Bio

PR CENTER

: 2019. 03. 25. ȸ : 2563 ÷ ٿε : ϵ ϴ.

[NEWS] ȸ ָ ӹ̿ '׾

1. ׾ ?

׾ ̴. 2 ко ְ ȸ ̸ ȸ Ű ̱ ݷζ Ű ۷Ϳ (Tumor metabolism) ȴ. Ű , ž, , ڻ ко߸ ٷ ְ ȸμ Ư ̹ ƿ ϼ Ư ׾ ǥ ٽ .

̱ Ű ȸ ƴ϶ ׾ Ȱϴ. 38 ϼ( ) 8 밭ǽǿ 2019 ũ(Cancer Metabolism Workshop) ִ.

̱ Ű ȸ ũ ġ о ֽ ϴµ ΰ ׾ ߵǰ ִ. мȸ ϼ Ư ϼ ༺, ̻¿ ϼ ̿ϴ , ϼ ܵ帮 , ̵  ǥ.

׾ Ӱ Ӽ 巯 а ָ ް ִ.

ù°, ߾ϼ ȯ 뵵 ο ׾ ɼ ߴٴ ̴. °, ο 翡 ޿ ̴߰. Cytosolic NADH: -ƽĸƮ Ʋ(malate-aspartate shuttle, MAS) ܵ帮 NADH Ͽ Complex 1 Ȱȭ Lactate () ֿ Ͽ ޿ õǾ. °, ũdzý (macropinocytosis): ܺοҸ ̴ , ̳ ̿ ๰ ֿ俬 õǾ. °, ÷ (Complex 1) 꿡 ʿ ް ɸ Ǿ , ο ߾ȭ ڷμ õǾ. , ڰ (Autophage): ü 鿪 ׾Ϲ 輺 Ǹ鼭 ̼ȯ ־ ֿ ָ޾Ҵ.

38 ֵ 2019 ũ(Cancer Metabolism Workshop) ϼ ڻ ʴ Ư ǥ ߰ϰ, ̸ Ͽ ڿ ߻ ϸ𵨿 پ ġ ȿ ν ġ ɼ ǥ ִ. (ϼ ϻп) žళҽþа ȸ ̹ ũ ̷ ġ ׾ ϴµ ⿩ϱ ٶ, ȯڿ ġ , ڿ ڶ , ӻǿ  غ ð DZ Ѵ Ϻ ִ.

4 ġ Ҹ ׾ ϼ 縦 Ͽ ʰ ϼ ϴ Ѹ ϼ ̴ ̴. ׾ 'ȭ׾(1) ǥ׾(2) 鿪׾(3)׾(4)' ϰ ִ. ׵ 1 ȭ׾ ϴ ۿ ߰, 2 ǥ׾ ִ Ǿ. , 3 Ҹ 鿪׾ 鿪ü踦 ڱ Ȱȭ 鿪 ϼ ϵ ϴ ´.

Ϻο Ŀ ̻ Ǻ Բ ' ' Ÿ⵵ ϸ ֱ 鿪 ̻ ϳ 嵶 ָް ִ 鿪׾ ۿ Ʈ ϰ ִ. ֱٿ 鿪׾ ȯڿ 11%16% ޼(Hyperprogression) ۿ Ͽٴ ʰ ǥ ǰ , ֱٿ ̷ ۿ ġȿ ̱ 2~3 ๰ Բ ϴ ǰ Ȱ ´.

߿ 1 ȭ׾ 2 ǥ׾ 鿪׾ 뿡 ߿ ִ. , 鿪׾ ׾ ó ȿ ̺ϱ 4 ׾ Ÿ ٶ ߼̱⵵ ϴ. ֱ ȸ 鿪׾ ̻ ← Ѵ ߴ.

2. ӹ̿ ׾ ϰ ΰ?

ӹ̿(HaimBio) ׾(NYH817100) Ҹ ܵ帮 ο ̵ .

ܵ帮ƿ  ü Ǵ ATP (Adenosine Tri-Phosphate) Ѵ. ATP ü Ű ȭп ϼ ʹ ٸ ۵θ ִ. ϼ  (lactate) .

PET-CT(ڴԿ) ã (lactate) κ ã ̷ ̸, ̸ ͹ Ʈ(Warburg-effect) θ. 1928 ߰ ͹״ η 뺧 ߴ. ٸ ֱٱ ϼ  η ؼ ü ʾҴٰ ϼ ڻ簡 Ǯ ΰ ãƳ´.

ù° ڻ ϼ ˵ Żȿ (ALDH) Ǿִٴ ָߴ. ϼ ALDH ̿Ͽ ȣ ش TCAȸο θ ̴NAD ȯ ޹(NADH) ܵ帮Ʒ ܵ帮Ƹ ް迡 ϴ Oxphos ̿ (ATP) Ѵٴ ߰ߴ.

ڻ ư ALDH ϴ NYH817G ϼ ռ ߰ Ͽ ϼ ϴ ᱹ ۿ ߰ߴ. ι° 索 ġ Ǿ NYH100P ߰ϸ ޿ ϼ 80~90% ܵǴ ȿ Ȯߴ. ̱ 索ȯڰ Ͽ ɸ Ȯ ٴ . ڻ Ÿٰ ó ڸ 'Cell death & disease' м ָ ޾Ҵ. Ѹ NYH817100 ϼ ο ٽ ϴ ϴ NYH817G NYH100P 縦 ϴ ġ, ջ ʰ ϼ ̴ ġ.

ӹ̿ 4 ׾(NYH817100) Ư ȿ ִ ǥġ ⺸ٴ Ǽ ִ ϼ Ư Ǵ ๰̱ 翡 ʰ ϼ δ. ׾ Ѱ غ ִ ׾̱⵵ ϴ. ϼ ٽ ˷ '˵ Żȿ(ALDH)' ȭ λȭ(Oxphos) , , ȿ ŹϿ κ ġȿ ŵ ϰ , а迡 ָϰ ִ.

3. ӹ̿ ġ ִ°?

а ̿ ׾ ߿ ϰ ִ. о ڰ 4 ׾ NYH817100 ӹ̿. ׾ ϰ ȿ ȹ ÷ ׾ ǵ Ѳ ٲ ǰ Ӿ ̸ Ű ġϴµ ִ ڵ鵵 ϼ ǥ ϴ ׾ ο ɼ ְ ִٰ ϰ ִ. 򰡹޾Ҵ 3 鿪׾ 鿪, ۿ Ǵ Ȳ ϼ ̴ 4 ׾ ָ ް 翬 .

4. ӹ̿ Ư?

ӹ̿ 2016 ϼ( ڻ) б (ȣ , ) , , ׾ 2017 ϼ ׾ Ư ޾ ׾ ϰ ִ.

2018 9 ϼͷκ NYH817100 ϴ ׾ ó ִ ǥ׾ ǥ ׾ Ư ߰ ޾Ҵ. ӹ̿ ϰ ִ , , Ư ̱ , Ϻ Ͽ, Ͽ Ͽ ߿ ִ.

߰ , , , , , , , Ҿ, , , 11 ġῡ ȿ ִ Ư㵵 ߿ ִ. ӻ1 Ǹ ӹ̿ 4 ġ õ ԰ ÿ ӻ迡 ǹ̸ ȴ.

5. ӹ̿ Ȳ?

ľó IND Ŀ ӻ CRO Բ б First-In-Human ӻ1 ̴. ӻ1 ϸ, ӻڿ ӻ , , , ๰ ȿ Ȯϴµ ִ. , ๰ ϰ ִ 뷮 ü ๰ ϰ, ๰ ü Ȯο ΰ ǽѴ.

ӻ2 Ʈδ ܿ ؿܿ site CROü ߿ ִ. ӻ2 ӻ1 , δ Ͼ 2 ǽ ٸ Ȯ븦 ϴ Ȱ Ͽ IND ÿ ߿ 1 ȿ ̴.

, 11̳ ǹǷ, Ϻ licensing out ɽ ִ. ̱ 쿡 ̱ FDA Pre-IND meeting Ͽ ̴. , ӻ ޹ħ ϰ ִ.

Ȯ ȯ , , ׾ ׾ ȿɿ / Ƿ ϰ ִµ ׾ ӻ 2 ڷḦ ϰ ֱ ܰ迡 ִ å κ ӻ Ȯ ϴ ִ. , ׾ ʷ ٰȭ ۾ ̴. ׾ ۿ ľϱ ȭ/ܹü ʿ ׾ ο λ MRC ܰ ߿ ִ. üȭǸ žళ å û ̸, , , ׾Ͽ Ư 2020 Ư Ͽ Ư Ű ϼ ǥ ϰ ִ.

6. ӹ̿ ǥ?

ӹ̿ ֱ ηκ 2019 IP-R&D հ Ǿ. 238 縦 Ϻ ȸ 8  ۷ι ɴ(Takeda) ȸ ׼(Axcelead) Ű ޵ (Sekisui Medical) ӹ̿ ǥ ִ. ׾Ͻ忡 ӹ̿ ǥ ׾ κ ȿ ִ ġᰡ ̷ ϴ ̴. ǥ׾ Ǵ 鿪׾ ߷ Ư â԰ ÿ پ ׾ Ȯ 簡 4 ׾ ߽ Ըϸ ̴. ׸ ׾ پ Ƿ忡 ׾ó ̷ ֵ Ű ̴.

׵ ġϱ ̾ پ ġ ߴ. ġȿ, ۿ, ġټ 巯 ִ. ̿ ϰ ڵ 5~6 ϼ Ÿ ϴ翡 ָϰ ϰ ִ. ʷ ׾ ӻ ġ ӹ̿ ε ž ߿ ִ R&DȰ źź ġ õ ȸμ ۷ι ȸ ϴ ǥ ϰ ִ.